louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05323578: Consumption Status of Caffeine and Adverse Effects Experience Among Anesthetists
Official title: Consumption Status of Caffeine and Adverse Effects Experience Among Anesthetists
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Caffeine
Caffeine Withdrawal
Caffeine Dependence
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-04-12
Enrollment: 168
Sex: ALL
Minimum age (years): 24
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Almost all anesthetists who approved to continue the survey.

Brief summary: High-caffeine consumption has been increasing in physicians, frequently causing the most common symptoms such as tremor, insomnia, anxiety, and nervousness and rarely leading to serious adverse effects like seizure, acute mania, and stroke due to caffeine overdose. There have been no studies regarding analysis of high-caffeine consumption and its adverse effects among anesthetists.

Detailed description: This study was to examine high-caffeine consumption patterns, associated factors, and adverse effects based on responses anesthetists with different age of experience.

Eligibility criteria: Inclusion Criteria:

* Any anesthetist

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: The prevalence of caffeine consumption among a sample of anesthesiologists, to determine their caffeine daily intake in relation to the safe level suggested by the European Food Safety Authority (EFSA).
timeFrame: 24 hours
measure: Subgroup comparison between junior and senior anesthetists
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Hospitals
Study officials:
affiliation: Ain Shams University
name: Raham H Mostafa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00231478: A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Official title: A Randomized, Double-blind Study of 2 Dose Levels of Kytril on the Prevention of Post-operative Nausea and Vomiting in Pediatric Patients Undergoing Surgery With General Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Post-Operative Nausea and Vomiting
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2005-10-04
Enrollment: 171
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This 2 arm study will evaluate the efficacy and safety of a single intravenous injection of Kytril in preventing postoperative nausea and vomiting (PONV) in children. Patients will be randomized to receive a single dose of either 20 micrograms or 40 micrograms Kytril intravenously (iv) 15 minutes prior to the end of surgery with general anesthesia for tonsillectomy or adenotonsillectomy. The anticipated time on study treatment is \<3 months, and the planned sample size was 170 patients.


Eligibility criteria: Inclusion Criteria:

* males and females 2-16 years of age
* scheduled to undergo elective surgery for tonsillectomy or adenotonsillectomy requiring general anesthesia and endotracheal intubation
* scheduled for hospital admission for no longer than 24 hours

Exclusion Criteria:

* known allergy or other contraindication to the use of Kytril or any of its components
* known allergy to any other 5HT3 antagonist
* history of motion sickness or post-operative nausea or vomiting
* nausea or vomiting in the 24 hours prior to anesthesia

Primary outcomes:
measure: Number of Patients With no Vomiting
timeFrame: 0-2h after end of surgery (time of extubation)
Secondary outcomes:
measure: Number of Patients With no Vomiting
timeFrame: 0-24h after time of extubation
measure: Time to First Vomiting Episode
timeFrame: 0-24h after time of extubation
measure: Adverse Experiences
timeFrame: infusion to 15 days post treatment
Other outcomes:
Locations:
city: Fresno
country: United States
state: California
city: Stanford
country: United States
state: California
city: Hartford
country: United States
state: Connecticut
city: Miami
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Indianapolis
country: United States
state: Indiana
city: Baltimore
country: United States
state: Maryland
city: Boston
country: United States
state: Massachusetts
city: Pittsburgh
country: United States
state: Pennsylvania
city: Nashville
country: United States
state: Tennessee
city: Dallas
country: United States
state: Texas
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT02104778: Effect of Dexamethasone and Epinephrine on the Duration of Sciatic Nerve Blocks With Ropivacaine
Official title: Effect of Dexamethasone and Epinephrine on the Duration of Sciatic Nerve Blocks With Ropivacaine in Ankle and Foot Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Yeungnam University College of Medicine
Sponsor class: OTHER
First posted: 2014-04-04
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to test that adding dexamethasone or epinephrine significantly prolongs the duration of sciatic nerve blocks with ropivacaine and that the magnitude of the effect differs among dexamethasone and epinehrine.

Detailed description: In a double-blinded trial utilizing single-injection sciatic nerve block, patients are randomly assigned to one of three groups: control: 0.5% ropivacaine adding normal saline; epinephrine: 0.5% ropivacaine adding epinephrine; dexamethasone: 0.5% ropivacaine adding dexamethasone. We assess time to first analgesic request after post-anaesthesia care unit discharge.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists physical status I and II
* patients undergoing elective hallux valgus repair

Exclusion Criteria:

* patients receiving chronic analgesic therapy
* diabetes
* peripheral neuropathies
* psychiatric disorders
* hypersensitivity to amide local anesthetics
* renal disorders

Primary outcomes:
measure: time to first analgesic request after postanesthetic care unit discharge
timeFrame: from arrival in postanesthetic care unit to 72 hours after operation
Secondary outcomes:
measure: time of recovery of motor and sensory functions on the operated foot
timeFrame: from arrival in postanesthetic care unit to 72 hours after operation
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Yeungnam University hospital
Study officials:
affiliation: Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea
name: Sangjin Park, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06301178: Effect of Vitamin D Injection on Hypertrophic Scars and Keloids
Official title: Effect of Vitamin D Injection on Hypertrophic Scars and Keloids
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Dermatologic Disease
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Scars and keloids cause patients severe morbidity and psychological distress. Hypertrophic scars rise above the skin but stay within the scar boundaries, while keloids expand.

The development of keloids and hypertrophic scars is a consequence of insufficient wound healing. These lesions are distinguished by excessive ECM deposition. Excessive ECM deposition is caused by increased inflammatory and proliferative processes and decreased remodeling activities. These scarring lesions are also linked to genetic and systemic causes


Eligibility criteria: Inclusion Criteria:

- Age from 12 years to 50 years. Patients with hypertrophic scars and keloids

Exclusion Criteria:

Age below 12 years and above 50 years. Patients received other treatment modalities for hypertrophic scars and keloids.

Systemic and other skin diseases. Patients were already receiving supplemental vitamin D.

Primary outcomes:
measure: Clinical scoring by Vancouver Scale Score
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: faculty of medicine-Fayoum university
Study officials:
References:
Clinical trial NCT01024478: Contrast-Enhanced Whole-Heart Coronary Magnetic Resonance Angiography at 3.0-T: A Multicenter Trial
Official title: Contrast-Enhanced Whole-Heart Coronary Magnetic Resonance Angiography at 3.0-T: A Multicenter Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Coronary Artery
Magnetic Resonance Angiography
Coronary Artery disease
Multicenter Trial
Cardiac MRI
Lead sponsor: Capital Medical University
Sponsor class: OTHER
Collaborators: name: Fujian Medical University Union Hospital
name: Air Force Military Medical University, China
name: Huazhong University of Science and Technology
name: Nanjing Medical University
name: First Affiliated Hospital, Sun Yat-Sen University
name: Henan Provincial People's Hospital
name: Fudan University
First posted: 2009-12-02
Enrollment: 272
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive eligible patients scheduled to undergo conventional coronary angiography.

Brief summary: The multicenter study evaluates the diagnostic performance of 3.0 T contrast-enhanced whole-heart coronary MRA in patients with suspected coronary artery disease.

Detailed description: This is a multicenter trial evaluated the diagnostic ability of 3.0 T contrast-enhanced whole-heart coronary MRA to detect significant coronary artery stenosis among patients with suspected CAD.

A total of 272 patients will be prospectively enrolled from 8 cities in China.

Eligibility criteria: Inclusion Criteria:

* Suspected CAD, scheduled for DSA
* Sinus rhythm

Exclusion Criteria:

* Contraindications to MR examination: pacemaker, intraauricular implants, intracranial clips, thoracotomy, claustrophobia, orthopnea
* Acute coronary syndrome
* Atria fibrillation
* Coronary stents
* Bypass grafts
* Renal insufficiency (estimated glomerular filtration rate assessed by creatinine clearance \<60 ml/min/1.73 m2)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Radiology Department of Xuanwu Hopital
state: Beijing
Study officials:
affiliation: Xuanwu Hospital, Beijing
name: kuncheng li, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yang Q, Li K, Liu X, Bi X, Liu Z, An J, Zhang A, Jerecic R, Li D. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-T: a comparative study with X-ray angiography in a single center. J Am Coll Cardiol. 2009 Jun 30;54(1):69-76. doi: 10.1016/j.jacc.2009.03.016.
Clinical trial NCT02213978: A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
Official title: A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Venous Thromboembolism
Hemorrhage
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
First posted: 2014-08-12
Enrollment: 1114
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: the critical ill patients in ICUs

Brief summary: The purpose of this study is to analyze the effect of the prophylaxis of venous thromboembolism in the critical ill patients, and at the same time, to find out the risk of venous thromboembolism and hemorrhage events occurred under the prophylaxis.


Eligibility criteria: Inclusion Criteria:

* all the patients in ICUs estimated time in ICU mare than 48h

Exclusion Criteria:

* estimated time in ICU less than 48h refused to attend

Primary outcomes:
measure: the incidence of venous thromboembolism under the thromboprophylaxis in critical ill patients
timeFrame: 2 weeks
Secondary outcomes:
measure: the incidence of bleeding events under thromboprophylaxis in critical ill patients
timeFrame: 2 weeks
Other outcomes:
measure: the incidence of venous thromboembolism under the mechanical thromboprophylaxis in the critical ill patients who with the contraindications to anticoagulation
timeFrame: 2 weeks
Locations:
city: Beijing
country: China
facility: Department of respiratory and critical care medicine,Beijing Chao-yang Hospital
state: Beijing
Study officials:
affiliation: Beijing Chao-Yang Hospital,China
name: Xiao Tang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00362778: Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia
Official title: Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes
Hyperglycemia
Acute Myocardial Infarction
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
First posted: 2006-08-10
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hyperglycemia at admission has been associated with bad prognosis in patients with acute myocardial infarction (AMI). The clinical benefit of intensive treatment with insulin has been evaluated in diabetic patients admitted to intensive care units. The aim of our study was to assess the short-term effects and the safety of strict glycemic control in subjects with AMI and hyperglycemia without a previous history of diabetes.

Detailed description: Twenty-eight non-previously diabetic patients admitted with AMI and hyperglycemia were randomized to two treatment arms, administered during the first 48 hours: the intensive group (n=13) received intravenous insulin with target glycemia levels of 80-110mg/dL, while the conventional group (n=15) received subcutaneous insulin only when glycemia was ³ 160mg/dL. High-sensitivity C-reactive protein (HS-CRP) was determined at 48 hours and before discharge and an oral glucose tolerance test (OGTT) was performed at 1 month.

Eligibility criteria: Inclusion Criteria:

1. Confirmed diagnosis of AMI, either with or without ST segment elevation
2. Presence of high blood glucose at admission with no previously known diabetes mellitus (DM)

Exclusion Criteria:

1. Age under 18 years old
2. History of DM
3. Presence of other cardiopathies (dilated cardiomyopathy, valvular or hypertrophic heart disease)
4. Unstable AMI patients (haemodynamic instability or arrhythmic disorders)
5. Platelet aggregation or coagulation disorders
6. Severe conditions with an estimated short (under 1 year) life expectancy
7. Participation in other trials
8. Patient refusal to participate in the study

Primary outcomes:
measure: Glycemic control
timeFrame: first 48 hours
Secondary outcomes:
measure: High-sensitivity C-reactive protein levels
timeFrame: At 48 hours and aat hospital discharge
Other outcomes:
Locations:
Study officials:
affiliation: Cardiology Department. Hospital Clínic i Universitari Barcelona
name: Xavier Bosch
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04011878: Histopathological Examination of Iris Tissue in Buphthalmos
Official title: Histopathological Examination of Iris Tissue in Buphthalmos
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iris Disease
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-07-09
Enrollment: 11
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To revise the etiology of the primary congenital glaucoma in some infants.

Detailed description: Combined trabeculotomy trabeculectomy with mitomycin C was done in 11 eyes. Histopathological examination of the peripheral iris tissue specimen was done in all cases.

Eligibility criteria: Inclusion Criteria:

* infants under age of 2 years
* 1ery glaucoma

Exclusion Criteria:

* infants more than 2 years
* 2ery glaucoma
* previous glaucoma surgery

Primary outcomes:
measure: fibrovascular membrane over iris surface
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00692471: Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)
Official title: Assessment of Objective Sleep Disturbances in Orthostatic Intolerance Using Actigraphy
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Postural Tachycardia Syndrome
Orthostatic Intolerance
Sleep Disorders
Keywords: Sleep
Orthostatic tachycardia
POTS
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: National Center for Research Resources (NCRR)
First posted: 2008-06-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with the Postural Tachycardia Syndrome. The criteria include:

* an increase in heart rate on standing (from supine) of \>30 bpm
* in the setting of symptoms of cerebral hypoperfusion that are worse with standing and better when recumbent
* the symptoms are daily or almost daily
* the symptoms are chronic (lasting greater than 6 motnsh)

Brief summary: We propose to use actigraphy (measured by activity watches) as a tool to quantify sleep disturbances in patients with orthostatic intolerance compared with healthy control subjects. In this pilot study, we will test the null hypothesis (Ho) that there are no differences in the sleep quality between patients with orthostatic intolerance and healthy control subjects.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with orthostatic intolerance by the Vanderbilt Autonomic Dysfunction Center
* Control subjects will be free of orthostatic intolerance and other major medical problems, free of medications during the study
* Age between 18-65 years
* Male and female subjects are eligible.
* Able and willing to provide informed consent

Exclusion Criteria:

* Overt cause for postural tachycardia (such as acute dehydration)
* Self-report of pregnancy
* Inability to give, or withdrawal of, informed consent
* Other factors which in the investigator's opinion would prevent the subject from completing the protocol

Primary outcomes:
measure: Sleep Latency
timeFrame: 1 week
Secondary outcomes:
measure: Sleep Efficiency
timeFrame: 1 week
measure: Wake After Sleep Onset
timeFrame: 1 week
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Satish R Raj, MD MSCI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04333771: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Rheumatoid Arthritis
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-04-03
Enrollment: 566
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.


Eligibility criteria: Inclusion Criteria:

* Provide signed informed consent.
* RA diagnosis consistent with the 2010 ACR/EULAR criteria;
* Moderate to severe RA defined by 6 or more tender joints, 6 or more swollen joints (68- or 66-joint count), and an ESR of 28 mm/h or greater or a CRP level greater than 5mg/L.
* Subjects were required to have an inadequate response to treatment with csDMARDs before baseline.
* If subjects are taking permitted csDMARDs or low-dose corticosteroid orally at baseline , the stable doses should have lasted for more than 4 weeks already.
* BMI ≥18 kg/m2

Exclusion Criteria:

* Pregnant women or refuse to receive contraception during the study.
* Lab abnormality within 4 weeks of randomization as follows: WBC count \<3.0×10\^9/L；neutrophil count\<1.5×10\^9/L;hemoglobin level\<90.0 g/L ; platelet count \<100×10\^9/L; AST or ALT levels greater than the upper limit of normal; HBsAg or HCV or HIV antibody positivity.
* History of another autoimmune rheumatic disease ; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases.
* Previous treatment with JAK inhibitor or cytotoxic drugs; bDMARDs within 6 months of randomization; other strong immunosuppressants within 3 months of randomization.

Primary outcomes:
measure: ACR20 response rate at week 24
timeFrame: Week 24
Secondary outcomes:
measure: ACR20 response rate at week 52
timeFrame: Week 52
measure: ACR50 response rate at week 24 and week 52
timeFrame: Week 24 and week 52
measure: ACR70 response rate at week 24 and week 52
timeFrame: Week 24 and week 52
measure: Change from baseline in HAQ-DI score at week 24 and week 52
timeFrame: Week 24 and week 52
measure: Change from baseline in SF-36 score at week 24 and week 52
timeFrame: Week 24 and week 52
measure: DAS28-CRP <2.6 proportion at week 24 and week 52
timeFrame: Week 24 and week 52
measure: DAS28-CRP≤3.2 proportion at week 24 and week 52
timeFrame: Week 24 and week 52
Other outcomes:
Locations:
city: Liuzhou
country: China
facility: Liuzhou workers' Hospital
state: Guangxi
Study officials:
References: